Exelixis, INC.
At a glance
Employees500+
In business sinceNot reported
HeadquartersAlameda, CA
US patents173
SAM.gov UEIR47FPKTS9T63
CAGE code6WGQ0
Incorporated inDE
Brands
An exceptional employee experience
Accelerating impact in oncology
Row of test tubesThis company sells these brands.
- cancer medicines
- therapies
- metastatic colorectal cancer
- development
- clinical trials
Named on the company’s own website, read JUL 29, 2026
Open positions
Openings read from Exelixis, INC.’s own job board on Workday, last checked OCT 21, 2026. FactoryRegistry does not host applications — each title opens the posting where the company published it.
- Corporate Counsel, ContractsExelixis, INC. · Alameda, CA · posted OCT 20, 2026
- Data & AI Platform Engineer IIExelixis, INC. · Alameda, CA · posted OCT 20, 2026
- Senior Staff Engineer - Cloud Platform, Enterprise Integration & Application ArchitectExelixis, INC. · Alameda, CA · posted OCT 19, 2026
- Senior Medical Director, Clinical DevelopmentExelixis, INC. · Alameda, CA; Remote · posted OCT 19, 2026
- GU Field Based Marketing Director - Key Customer Team (Remote North East - NY, MA & CT)Remote · posted OCT 19, 2026
- Clinical Science DirectorExelixis, INC. · Alameda, CA; Remote · posted OCT 19, 2026
- Senior Oncology Account Manager - (Birmingham, AL | Remote)Remote · posted OCT 19, 2026
- Executive Medical Director, Pharmacovigilance Risk Management (PVRM)Remote · posted OCT 19, 2026
- Associate Clinical Supply Distribution DirectorExelixis, INC. · Alameda, CA; Alameda HQ · posted OCT 16, 2026
- Senior Scientist I, BioassayExelixis, INC. · Alameda, CA · posted OCT 16, 2026
53 more on the company’s board
Patents
173 US patents granted 2002–2025, 37 of them in the five years to SEP 2025.
Pharmaceuticals 93Organic fine chemistry 41Measurement 21Biotechnology 12Other special machines 3
- Pyridone compounds and methods of useUS 12,371,428 · granted JUL 29, 2025
- Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancerUS 12,275,706 · granted APR 15, 2025
- Heterocyclic adenosine receptor antagonistsUS 12,264,161 · granted APR 1, 2025
- Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of useUS 12,227,481 · granted FEB 18, 2025
- Compounds for the treatment of kinase-dependent disordersUS 12,195,475 · granted JAN 14, 2025
Newest 5 shown · Granted to Exelixis, Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Exelixis, INC. | Alameda | CA | 500+ | ACTIVE |
WARN Act notices
- Layoff notice effective OCT 27, 2025 · 71 employees · Exelixis, INC.
- Layoff notice effective AUG 29, 2025 · 74 employees · Exelixis, INC.
- Layoff notice effective MAR 8, 2024 · 143 employees · Exelixis, INC.
Filed with the state under the federal WARN Act · WARN Act notices feed, CC BY 4.0
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.